Introduction
There are three classes of PI3Ks, among which the Class I kinases (subdivided into IA and IB subsets) convert phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) in response to external cell stimuli (1, 2, 3) . Activation of Class IA PI3Ks (PI3Kα, -β, and -δ) is mediated by receptor tyrosine kinases (RTKs). G-protein-coupled hormone receptors are implicated in activation of PI3Kβ and Class IB PI3K (PI3Kγ) (4) . RAS can also directly bind to and activate p110α, the catalytic subunit of PI3Kα, and PI3Kα can mediate cellular transformation by RAS (2, 5) . Similarly, p110, the catalytic subunit of PI3K, interacts with and serves as an effector of the GTPases RAC and cell division cycle 42 (CDC42) (2, 6) . Downstream effectors of PI3K signaling, such as phosphoinositide-dependent kinase-1 (PDK1) and AKT, bind to PIP 3 at the cell membrane and are subsequently activated by phosphorylation, resulting in activation of signaling cascades regulating tumor proliferation, survival, angiogenesis, invasion, and dissemination (1, 2) . TORC1, a multisubunit complex including the mTOR catalytic subunit and Raptor, acts downstream of AKT and is itself a notable target for therapeutic intervention in cancer and other diseases (7, 8) .
Dysregulation of PI3K pathway components, resulting in upregulation of PI3K signaling, is observed in many cancers and is thought to promote tumor growth and survival (1, 2) .
PIK3CA, the gene encoding p110α, is the most frequently mutated kinase in human tumors, with mutations evident in approximately 10% of human cancers (9) . In addition, the tumor suppressor PTEN, which is a critical negative regulator of PI3K signaling that converts PIP 3 back to PIP 2 , is frequently deleted or downregulated in human tumors (1, 2, 10) . PTEN-deficient tumors are believed to be highly PI3K-dependent, although it has recently been demonstrated that this dependence can be shifted to PI3K by concurrent mutations that activate p110α (11) . In addition to PTEN, other tumor suppressor genes negatively regulating the PI3K pathway have been identified, including liver kinase B1 (LKB1), type II inositol polyphosphate-4-phosphatase, and tuberous
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In vitro kinase inhibition assays and PIP 3 Mass Balance Assay
Kinase inhibition assays and the PIP 3 mass balance assay were performed as previously described (14) .
pAKT and pS6 ELISA ELISA for pAKT T308 and total AKT were performed on PC-3 cell lysates and analyzed as previously described (14) . The pS6 ELISA was performed as previously described (15) with minor modifications.
Cell-based Assays
Cell lines were obtained from the American Type Culture Collection in 2001-2005 and maintained in culture conditions at 37°C under 5% CO 2 as previously described (14) . For PI3K pathway status assessment following EGF treatment, the culture medium was replaced with test compounds dissolved in serum-free DMEM containing 0.3% DMSO.
After incubation for 3 h, cells were stimulated with 100 ng/ml of EGF (R&D Systems, 236-EG) for 10 min and Western immunoblot analysis of cell lysates was performed as previously described (14) . Assessment of mTOR pathway status in Ramos cells was performed as previously described (14) . Cellular proliferation was assessed as previously described (16) using the Cell Proliferation ELISA, Bromo Deoxyuridine (BrdU) chemiluminescence kit (Roche, Applied Science). Cytotoxicity, apoptosis (Caspases 3/7), anchorage-independent growth, and PC-3 cell migration assays were performed as previously described (14) . HGF-induced chemotaxis was assessed as previously described (16) . The endothelial cell tube formation assay was performed as previously described (16) and tumor weights assessed as previously described (14) . Statistical significance was determined using the 2-tailed Student's t-test (significance defined as p<0.05). XL147
was formulated in sterile water/10 mM HCl or water and administered at the indicated doses and regimens by oral gavage at a dose volume of 10 mL/kg. Paclitaxel was purchased from MP Biomedicals (Irvine, CA) and formulated for intravenous (IV) administration by dissolution of the dry powder into 1:1 EtOH/Cremophor mixture, with subsequent dilution (1:3) into normal saline. Carboplatin was purchased from PolyMed Therapeutics (Houston, TX) and formulated for IV administration by dissolution in normal saline containing 0.5% EtOH/0.5%CremophorEL.
For Western immunoblot assessment, tumors were collected at the indicated time-points and tumor lysates were prepared, processed, and analyzed as previously described (14) .
For histological assessment, after euthanasia, tumors from animals administered XL147 and/or other agents were excised and fixed in zinc fixative (BD Pharmingen) for 24-48 h before being processed into paraffin blocks. Five µm thin sections were cut serially to represent the largest possible surface for each tumor and Ki67 nuclear antigen, CD31 positive tumor vessels, or apoptotic cells (TUNEL) detected and analyzed as previously described (14) . 
Results
XL147 is a selective inhibitor of class I PI3Ks in biochemical assays
XL147 was identified following optimization of a quinoxaline scaffold for in vivo PI3K pathway inhibition and drug-like properties (XL147 structure is shown in Figure 1A) . In assays performed using purified proteins in a luciferase-coupled chemiluminescence format, XL147 displayed potent inhibitory activity against Class I PI3K isoforms p110α, p110δ, and p120γ, with IC 50 values of 39, 36, and 23 nM, respectively ( Table S1 ). All assays were performed at ATP concentrations approximately equal to the Michaelis constant (K M ) values of the respective enzymes.
XL147 inhibits the PI3K pathway in multiple tumor cell models MCF7 human mammary carcinoma cells and PC-3 human prostate adenocarcinoma cells were selected for the initial assessment of the effect of XL147 on PTEN/PI3K pathway signaling because they harbor, respectively, a heterozygous E545K activating mutation in the PIK3CA subunit of PI3K and a homozygous deletion of exons 3-9 of the PTEN tumor suppressor gene. PIP 3 is the product of a class IA or IB PI3K acting on its physiological substrate PIP 2 . Hence PIP 3 levels serve as a direct assessment of PI3K activity. Consistent with its inhibitory activity against purified PI3K proteins, XL147 with IC 50 values of 220 and 347 nM, respectively ( Table 2 ). The ability of XL147 to inhibit phosphorylation of key signaling proteins downstream of PI3K was examined by assessing its effects on EGF-stimulated phosphorylation of AKT and on non-stimulated phosphorylation of S6 in PC-3 cells in serum-free media by cell based ELISA. XL147 inhibited these activities with IC 50 values of 477 and 776 nM, respectively ( Table 2 ).
The effects of XL147 on the PI3K signaling pathway were examined by Western immunoblot analysis in MCF7 and PC-3 cells (see Figure 1B and Supplemental Figure   S1 ). XL147 inhibited AKT phosphorylation at both activation sites (T308 and S473) at concentrations consistent with the IC 50 values determined by ELISA in MCF7 and PC-3 cells stimulated with EGF following incubation for 3 hours in serum-free medium containing XL147. Inhibition of AKT substrate phosphorylation (PRAS40 and GSK3β) and inhibition of phosphorylation events downstream of mTOR (p70S6K, S6, and 4EBP1 phosphorylation) were also evident. XL147 induces a decrease in the levels of cyclin D1 protein, consistent with increased GSK3β activity as a result of inhibition of AKT leading to GSK3β-mediated phosphorylation and subsequent degradation of Cyclin D1 ( Figure   1B and Supplemental Figure S1 ). In general, higher compound concentrations were required to inhibit phosphorylation events downstream of mTOR than more PI3K-proximal events such as AKT phosphorylation, consistent with selective inhibition at the PI3K level. XL147 does not inhibit nutrient-stimulated mTOR kinase activity in cells as assessed by S2481 autophosphorylation and p70S6K/4E BP1 phosphorylation, providing further evidence for lack of direct activity towards mTOR (Supplemental Figure S2 ).
The control compound ZSTK474 (an inhibitor of PI3K; Reference 17) at 10 µM robustly decreased the levels of all the phospho readouts assessed. The mTORC1 inhibitor rapamycin at 0.1 µM did not inhibit the phosphorylation of AKT or its direct substrates PRAS40 and GSK3β, but in fact appeared to stimulate phosphorylation of AKT. This is consistent with relief of p70S6K-dependent negative feedback of PI3K (2) . As expected, rapamycin significantly decreased pp70S6K and pS6 levels, consistent with its well characterized ability to inhibit TORC1. None of the compounds had significant effects on ERK1/2 phosphorylation. The ability of XL147 to inhibit phosphorylation of key signaling components of the PI3K pathway was also evident in the presence of 10% serum in PC 3 and MCF7 cells, although compound potency was reduced, presumably reflecting compound binding to serum proteins (Supplemental Table S2 Table S3 ). In general, PIK3A mutant and, to a lesser extent, PTEN mutant cell lines tended to be relatively sensitive to XL147, whereas RAS or BRAF mutant cell lines tended to be less sensitive. Interestingly, several RAS mutant cell lines were relatively insensitive to XL147 in spite of their also harboring PI3CA mutations ( Figure 2 and Supplemental Table S3 ). The micromolar IC 50 values demonstrated in these experiments may be attributable in part to the presence of 10% serum in these assays and the consistently high in vitro plasma protein binding exhibited by XL147 , with 99.9% of this agent bound in mouse, rat, and human plasma. Similarly, in vivo plasma protein binding, quantified in plasma samples from mice and rats administered XL147, showed plasma protein binding of 99.9% and 99.8% at 100 mg/kg dosages. All values were determined by an equilibrium dialysis method. As discussed previously, the presence of serum also causes a significant increase in the IC 50 values for XL147 inhibition of AKT and S6 phosphorylation. To rule out direct cytotoxic effects of XL147 on tumor cells, its effects on cell viability were determined by bioluminescent measurement of cellular ATP. XL147 did not reduce ATP levels when incubated for 24 h, indicating a lack of cytotoxicity (Supplemental Table S3 , footnote). Induction of cytoplasmic Caspases 3 and 7 was examined as an indication of apoptosis induction. XL147 did not affect the activity of these Caspases at the compound doses and time point tested (Supplemental Table S3 , footnote). In MCF7 cells, the anti-proliferative effects of XL147 were associated with a specific block in the G1 phase of the cell cycle and an increase of sub G1 cell population (Supplemental Table   S4 ). Therefore, at least in MCF7 cells, the anti-proliferative effects of XL147 in culture do not appear to be due to cytotoxic or pro-apoptotic effects, but rather reflect cytostasis.
XL147 inhibits tumor cell migration, invasion, and angiogenesis
One of the hallmarks of aggressive tumor cells is the ability to migrate in response to chemotactic stimuli and to invade surrounding tissue. HGF is one of the key stimulators of these behaviors, and cell lines expressing high levels of the HGF receptor MET, are highly invasive and metastatic in vivo. Since PI3K resides in the MET signaling pathway, the ability of XL147 to inhibit HGF-stimulated migration and invasion was tested using in vitro assays that measure these behaviors. Murine B16 melanoma cells express high levels of MET which becomes highly phosphorylated when the cells are treated with HGF. In 10% serum, B16 cells plated in the top well of a transwell chamber containing a barrier with 0.8 micron pores show very little ability to migrate to the lower chamber Tubules are stained and quantitated using an antibody that recognizes the endothelial cell marker CD31, as illustrated in Figure 3C . XL147 inhibited VEGF-induced tubule formation with an IC 50 of 529 nM, similar to the IC 50 value of ZD6474 (646 nM), an inhibitor of VEGFR2, PDGFRβ, FGFR1, and FLT4 that is known to inhibit angiogenesis (20) . Blood was collected at the same time tumor tissue was harvested in both studies and plasma concentrations of XL147 were assessed (Supplemental Table S5 ). Based on these data, the plasma concentrations required to inhibit phosphorylation of AKT, p70S6K, and S6 by 50% in these tumor models ranged from approximately 90 to 180 µM. Hence XL147 exhibited comparable pharmacodynamic activity in PIK3CA-mutant MCF7 and PTEN-deficient PC-3 xenograft tumor models. Multiple tumor models were utilized to explore the efficacy and potency of repeat-dose XL147 with regard to tumor growth inhibition in vivo. In addition to the previously described MCF7 and PC-3 models, the anti-tumor efficacy of XL147 was evaluated in xenograft models including OVCAR-3 (human ovarian xenograft tumor model exhibiting PIK3CA amplification), U-87 MG (human glioblastoma xenograft tumor model harboring a deletion at codon 54 in the gene encoding PTEN, resulting in a frameshift), A549 (human NSCLC xenograft tumor model harboring a homozygous activating mutation in KRAS and a homozygous loss-of-function mutation in LKB1), Calu-6 (human non-small cell lung carcinoma harboring mutationally activated KRAS Q61K), A2058
(PTEN-deficient human malignant melanoma harboring a homozygous V600E activating mutation in BRAF), and WM-266-4 (PTEN-deficient human malignant melanoma harboring a heterozygous V600D activating mutation in BRAF). Table S6 ) at doses that proved well tolerated as assessed by daily monitoring of mouse weights (Supplemental Figure S6) . The most efficacious once daily dose assessed was 100 mg/kg, suggesting that sustained pathway inhibition is required for maximal efficacy. This dose generally resulted in stasis or near-stasis of tumor growth, except in the case of the tumors harboring KRAS or BRAF mutations where tumors generally continued to growth although at a reduced rate ( Figure 6 and Supplemental Table S6 ). Immunohistochemical analysis of MCF7 tumors collected at the end of the dosing period revealed significant, dose-dependent decreases in staining for Ki67, a marker of cell proliferation (Table 3) . Similarly, administration of XL147 at 100 mg/kg once daily for 2 weeks resulted in a 51% decrease in Ki67 staining in PC-3 tumors. Moreover, decreased tumor vascularization was also observed in MCF7, PC-3, and Calu-6 tumors (Table 3 and Figure 6 ). Thus, inhibition of PI3K by XL147 results in an anti-proliferative effect, as well as a modest anti-vascular effect in xenograft tumors.
XL147 exhibited significant anti-tumor efficacy in vivo in all of these models (Figures 5 and 6, and Supplemental
In PC-3 and Calu-6 tumors there was also evidence for increased apoptosis as judged by TUNEL staining (Figure 6 ) although the absolute percentage of TUNEL positive tumor cells remained small, suggesting that increased apoptosis was not a significant contributor to anti-tumor efficacy. Plasma concentrations at the end of these efficacy studies were higher than those evident following single-dose administration, presumably reflecting Table S5 ).
In addition to its anti-tumor efficacy as monotherapy, XL147 potentiated the anti-tumor efficacy of the cytotoxic agents paclitaxel and carboplatin ( Figure 6 ). When XL147 was combined with paclitaxel or carboplatin apoptosis was induced to an extent greater than that seen for either agent alone while there was also an enhanced reduction in tumor angiogenesis evident ( Figure 6 ). It is noteworthy that XL147 administered in these combinations proved generally well-tolerated as assessed by daily monitoring of mouse body weights (Supplemental Figure S6) . 
A major cause of PI3K activation in human tumors is gain of function mutations in PIK3CA, particularly in Exons 9 and 20 which encode the helical and kinase domains of the p110 catalytic subunit of PI3K (3). Molecular alterations directly affecting PI3KB are rare in human cancer (1), but PI3K is considered to be the major driver of dysregulated PI3K pathway activity associated with PTEN deficiency, although PI3Kα may be the more important isoform in PTEN-deficient tumors where p110α is concurrently activated by mutated RAS (11) . Hence, concerted inhibition of PI3Kα and PI3K is likely desirable in terms of broad potential utility in treating solid tumors. In biochemical assays, XL147 appears to be more potent against PI3K than against PI3K (Table 1) . However, in cellular assays XL147 shows comparable activity versus PI3K pathway signaling in MCF7 breast (PIK3CA mutant) and PC-3 prostate (PTENdeleted) tumor cells. Moreover, XL147 showed comparably pharmacodynamic activity against these cell lines when they were grown as xenograft tumors in mice. These data demonstrate that XL147 exhibits functionally equivalent activity against PI3K and PI3K in cultured cells and preclinical tumor models.
XL147 exhibited a wide range of anti-proliferative activity against tumor cells grown as monolayers. In MCF7 cells, these effects were associated with a G1 arrest, but not with acute cytotoxicity or induction of apoptosis. There was a trend suggesting enhanced sensitivity of cells exhibiting PIK3CA mutations to XL147, consistent with similar observations previously reported for the PI3K inhibitors GDC-0941 and CH5132799 (21, 22) . Likewise, the relative insensitivity of RAS mutant cell lines, regardless of PIK3CA status, to inhibition of proliferation by XL147 is consistent with preclinical observations with other PI3K pathway targeting agents (23) .
When administered as monotherapy, XL147 showed efficacy in models with diverse genetic lesions activating the PI3K pathway, specifically a PIK3CA E545K mutation (MCF7), PIK3CA amplification (OVCAR-3), PTEN deletion/deficiency (PC-3, U-87 MG, A2058, WM-266-4), KRAS mutation (A549 and Calu-6), and LKB1 mutation (A549). The fact that efficacy was observed in all these models suggests that XL147 may 
have broad utility in tumors with activation of the PI3K pathway. It is intriguing that, of these models, XL147 appeared to be least efficacious against Calu-6, a KRAS-mutant tumor lacking detectable genetic alterations in PIK3A, PTEN, or LKB-1. Based on IHC/IF analyses efficacy across models was likely mediated by a combination of antiproliferative and anti-angiogenic effects (Table 3 and Figure 6 ). The plasma concentrations associated with pharmacodynamic activity and anti-tumor efficacy in mice are comparable to plasma concentrations associated with PI3K pathway inhibition in a single-agent Phase 1 clinical study (compare Supplemental Table S5 
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